Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PVLA vs IBRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBRX Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–3 Matrix Metrics)

IBRX Overall Winner 6-Pillar Tally: PVLA 1 – 4 IBRX (1 Tie) Matrix Metrics: PVLA 3 – 6 IBRX

As of Nov 16, 2026, ImmunityBio, Inc. (IBRX) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas IBRX carries 52.8/100 (HOLD) at $6.03 (66.7x Forward P/E, -150.2% operating margin).

  • Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile IBRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PVLA vs IBRX
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42
IBRX NASDAQ Head-to-Head Winner
ImmunityBio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.03
+0.08% 1D
Market Cap $6.5B
TTM Revenue $183M
Forward P/E 66.7x
Beta / 30D Vol 1.68β · 103% Vol
Unified Composite Score
52.8 / 100 HOLD
Tech 53.0 Fund 56.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.3%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $7.84 · SMA50: $8.55

6-Pillar Scorecard Institutional Category Breakdown (PVLA 1 – 4 IBRX)

Columns: Metric · PVLA · IBRX
1. Valuation Multiples IBRX
Forward P/E N/M 66.7x
Trailing P/E N/M 66.7x
PEG Ratio N/M N/M
EV / Revenue N/M 39.9x
2. Growth & Scale IBRX
Revenue Growth (YoY) +0.0% +52.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $183M
Market Cap $2.2B $6.5B
3. Profitability & Quality IBRX
Gross Margin N/A 98.8%
Operating Margin 0.0% -150.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -63.4% 0.0%
4. Balance Sheet & Cash Flow PVLA
Cash Generation (TTM) -$43M -$297M
Cash Flow Margin N/A N/A
Net Cash / Leverage $193M Net Cash $824M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IBRX
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 47.9% (2nd %ile) 93.0% (16th %ile)
Put/Call OI Skew 3.82x (Put-Skewed) 1.05x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PVLA (3) vs IBRX (6)
Institutional Metric PVLA IBRX Criterion Row Edge
Market Capitalization
Scale
$2.2B $6.5B Larger Scale IBRX
Trailing P/E Ratio
Valuation
N/M 66.7x Lower Multiple IBRX
Forward P/E Ratio
Valuation
N/M 66.7x Lower Multiple IBRX
Revenue Growth (YoY)
Growth
+0.0% +52.3% Higher Growth IBRX
Operating Margin (TTM)
Profitability
0.0% -150.2% Higher Margin PVLA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-63.4% 0.0% Higher ROE IBRX
52-Week Range Position
Momentum
68% ($72–$180) 39% ($2–$12) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.66β · 75% Vol 1.68β · 103% Vol Lower Realized Risk PVLA
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 52.8 / 100 (HOLD) Higher Composite IBRX
Trailing 12M Revenue (USD)
Operating Scale
N/A $183M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 98.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 39.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M ($193M Net Cash) -$297M ($824M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +54.93 pp
PVLA: +20.56% · IBRX: -34.37%
3M Horizon PVLA +18.38 pp
PVLA: -3.58% · IBRX: -21.96%
6M Horizon PVLA +62.75 pp
PVLA: +38.06% · IBRX: -24.69%
1Y Horizon IBRX +121.09 pp
PVLA: +80.16% · IBRX: +201.25%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PVLA Revenue IBRX Revenue PVLA Op. Margin IBRX Op. Margin Margin Leader
FY2018 $30M $0M -113.1% -209338.3% PVLA
FY2019 $40M $0M -62.2% -7095.9% PVLA
FY2020 $30M $0M -115.7% -36509.1% PVLA
FY2021 $30M $0M -165.0% -35361.9% PVLA
FY2022 $30M $0M -167.8% -146374.2% PVLA
FY2023 $40M $0M -27.7% -58239.5% PVLA
FY2024 N/A $10M N/A -2334.2% IBRX
FY2025 N/A $110M N/A -226.0% IBRX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IBRX BREAKDOWN
26d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 16th %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact IBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.5B market capitalization and -150.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PVLA vs IBRX Key Questions & Quantitative Answers

As of Nov 16, 2026, ImmunityBio, Inc. (IBRX) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas IBRX carries 52.8/100 (HOLD) at $6.03 (66.7x Forward P/E, -150.2% operating margin). Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile IBRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBRX leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IBRX at +52.3% YoY revenue growth and +0.0% YoY earnings growth on $183M TTM revenue (98.8% gross margin, -150.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PVLA cumulative revenue shifted +33.3% while IBRX shifted +1000.0%. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBRX.

IBRX screens cheaper on headline valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IBRX trades at 66.7x Forward P/E, 66.7x Trailing P/E, N/M PEG, and 39.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus IBRX (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, IBRX carries 93.0% implied volatility (16th %ile, Compressed (<25th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 103% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.